Fig A6.

Overall survival (OS) of patients with advanced-stage lung adenocarcinoma not treated with immunotherapy. Survival is shown on the basis of tumor mutation burden above or below the (A) 25th, (B) 50th, (C) 75th, and (D) 90th percentiles within the non–immune checkpoint inhibitor non–small-cell lung cancer advanced-stage cohort (n = 609). The hazard ratios for OS at each cut point were as follows: 25th percentile, 0.49 (P < .001); 50th percentile, 0.58 (P < .001); 75th percentile, 0.81 (P = .118); and 90th percentile, 0.82 (P = .338).